Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter

• US 7,960,137 B2
• Filed: 01/25/2010
• Issued: 06/14/2011
• Est. Priority Date: 10/07/2002
• Status: Expired due to Fees

• Current Assignee: Biogaia AB
• Original Assignee: Biogaia AB
• Inventors: Connolly, Eamonn, Mollstam, Bo
• Primary Examiner(s): Lilling; Herbert J.
• Application Number:
  US12/657,655
• Publication Number:
  US 20100129337A1
• Time in Patent Office: 505 Days
• Field of Search: None
• US Class Current: 435/34
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A23V 2400/173 Reuteri
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12P 21/00 Preparation of peptides or proteins single cell protein C12N1/00
• CPC Class Codes: C12R 2001/225 Lactobacillus

Abstract

Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

Claims

1. A composition produced according to a method comprising the steps of:

a) selecting and culturing a Lactobacillus strain;

b) obtaining a cell-free culture supernatant from said strain;

c) evaluating the level of TNF-alpha in the supernatant using a model system, wherein a reduction in the level of TNF-alpha identifies a lactic acid bacteria strain;

d) selecting said lactic acid bacteria strain; and

e) producing a composition comprising either cells of the strain selected in d) or a Helicobacter pylori associated inflammation-reducing component containing proteins or peptides and derived from the cell-free culture supernatant of said strain,

wherein the composition is for administration to a mammal for reducing gastrointestinal inflammation associated with Helicobacter pylori infection in the gastrointestinal tract of said mammal.

2. The composition of claim 1, wherein the lactic acid bacteria strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660.

3. The composition of claim 1, wherein said composition is a food composition comprising an ingestible support and the Helicobacter pylori associated inflammation-reducing component.

4. The composition of claim 2, wherein said composition is a food composition comprising an ingestible support and cells of the lactic acid bacteria strain.

5. The composition of claim 2, wherein said composition is a pharmaceutical composition comprising a pharmaceutical carrier and the Helicobacter pylori associated inflammation-reducing component.

6. The composition of claim 2, wherein said composition is a pharmaceutical composition comprising a pharmaceutical carrier and cells of the lactic acid bacteria strain.

7. The composition of claim 2, wherein said composition is a nutritional supplement comprising an ingestible support and the Helicobacter pylori associated inflammation-reducing component.

8. The composition of claim 2, wherein said composition is a nutritional supplement comprising an ingestible support and cells of the lactic acid bacteria strain.

9. The composition of claim 2, wherein said composition is an agent for treatment or prophylaxis of inflammation associated with Helicobacter pylori.